1st International and 10th National Iranian Conference on Bioinformatics

Microarray analysis for Glioblastoma drug-repositioning

Paper ID : 1094-ICB10

Authors:

zahra alaeddini *

Abstract:

Background: Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells. Glioblastoma can occur at any age but tends to occur more often in older adults. One of the most important things to treat this type of brain cancer is an appropriate drug, but drug discovery is a high-priced pipeline that may be taken a long time to achieve a good component that satisfies most of the pharmacokinetic assays for our interested disease. One way to reach this aim is the drug repositioning that we investigate in this research.
Materials and Methods: We downloaded GSE4290 from the GEO database for our purpose and did an analysis on it by R. After that we extracted genes that had high expression by setting LogFc >1 and adj.p.val < 0.05. These genes did input as queries on the Enrichr web tool for investigating diseases pathway that these genes have an effect on them. One of the diseases based on the KEGG 2021 Human, was small cell lung cancer. We search on ChEMBL for small cell lung cancer relative compounds.
Results: by filtering on the ChEMBL results based on the Lipinski and Ghose, drug-likeness roles, we compared the SMILE structures of TALAZOPARIB[3] which is accessible by results filtering, and EVEROLIMUS that is used for Glioblastoma treating, on the Swiss ADME. The TALAZOPARIB satisfies all Drug-likeness assays than EVEROLIMUS and based on the ChEMBL references TALAZOPARIB is used for treating many types of cancers, so we can use instead of EVEROLIMUS.
Conclusion: When drug discovery has a huge financial load on drug companies, drug repositioning is a good and fast choice for them to provide the best drug component with satisfying most of the pharmacokinetic assays and drug-likeness roles.

Keywords:

Glioblastoma; Drug repositioning; drug discovery; cancer

Status : Paper Accepted (Poster Presentation)